Synonyms: A-301 | ATI-50002 | ATI-502
Compound class:
Synthetic organic
Comment: The chemical structure that was submitted to the WHO for the INN ifidancitinib matches one of the that are claimed as Janus kinase (JAK) inhibitors in Rigel Pharmaceuticals' patent WO2012015972A1 [1]. Structurally ifidancitinib is identical to fosifidancitinib (fosifidancitinib) but without the phosphate group. The closest structural match in the patent is example I-221 but this has deuterium iotopes replacing some of the hydrogens on methylanilino group. This compound has been matched to ATI-502 which was developed as a topical agent for dermatological applications.
|
|
Immunopharmacology Comments |
JAK2/3 inhibitors have clinical application in the treatment of inflammatory conditions via downregulation of pathological JAK-STAT pathway activation. In particular JAK3 appears to associate with the common gamma chain (γc) of various cytokine receptors and is therefore important for the cellular responses to a wide range of cytokines including IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. |